PDCD1 and neoplasm: Programmed cell death 1(PD-1)/PD-1 ligand (PD-L1) checkpoint blockade is a promising clinical anticancer treatment modality by blocking the binding of PD-L1 on tumor cells to PD-1 on activated T cells to reactivate T-cell-mediated antitumor immunity1–3.